O039 Cerebral Blood Flow, Endothelial Function In Patients With Coronary Artery Disease And Arterial Hypertension Receiving Ivabradine In Combination With Perindopril

Musikhina, N.; Gapon, L.; Utesheva, Alena; Petelina, T.; Кузнецов, В. А.

doi:10.1016/j.gheart.2014.03.1255

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the controversial candidates for the treatment of ED is the if-channel inhibitor ivabradine. A number of studies have revealed its positive effect on both endothelium-dependent vasodilation and eNOS expression in both animals and humans (Bolduc et al 2011;Musikhina et al 2012;Orea-Tejeda et al 2013). However, the authors of some studies note that there was no significant improvement in vasodilation under the action of ivabradine in patients with microvascular angina (Villano et al 2013), as well as in patients with other forms of coronary heart disease (Jochmann et al 2014) or type II diabetes (Nerla et al 2012).…”

Section: Therapeutic Strategiesmentioning

confidence: 99%

Endothelial dysfunction: developmental mechanisms and therapeutic strategies

Shcheblykin¹,

Bolgov²,

Pokrovsky³

et al. 2022

RRP

View full text Add to dashboard Cite

Introduction: Every year the importance of the normal functioning of the endothelial layer of the vascular wall in maintaining the health of the body becomes more and more obvious. The physiological role of the endothelium: The endothelium is a metabolically active organ actively involved in the regulation of hemostasis, modulation of inflammation, maintenance of hemovascular homeostasis, regulation of angiogenesis, vascular tone, and permeability. Risk factors for the development of endothelial dysfunction: Currently, insufficient bioavailability of nitric oxide is considered the most significant risk factor for endothelial dysfunction. Mechanisms of development of endothelial dysfunction: The genesis of endothelial dysfunction is a multifactorial process. Among various complex mechanisms, this review examines oxidative stress, inflammation, hyperglycemia, vitamin D deficiency, dyslipidemia, excess visceral fat, hyperhomocysteinemia, hyperuricemia, as well as primary genetic defect of endotheliocytes, as the most common causes in the population underlying the development of endothelial dysfunction. Markers of endothelial dysfunction in various diseases: This article discusses the main biomarkers of endothelial dysfunction currently used, as well as promising biomarkers in the future for laboratory diagnosis of this pathology. Therapeutic strategies: Therapeutic approaches to the endothelium in order to prevent or reduce a degree of damage to the vascular wall are briefly described. Conclusion: Endothelial dysfunction is a typical pathological process involved in the pathogenesis of many diseases. Thus, pharmacological agents with endothelioprotective properties can provide more therapeutic benefits than a drug without such an effect.

show abstract